Logo image of MNPR

MONOPAR THERAPEUTICS INC (MNPR) Stock Fundamental Analysis

NASDAQ:MNPR - Nasdaq - US61023L2079 - Common Stock - Currency: USD

44.96  +1.81 (+4.19%)

Fundamental Rating

3

MNPR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 563 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MNPR as it has an excellent financial health rating, but there are worries on the profitability. MNPR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MNPR has reported negative net income.
MNPR had a negative operating cash flow in the past year.
MNPR had negative earnings in each of the past 5 years.
MNPR had a negative operating cash flow in each of the past 5 years.
MNPR Yearly Net Income VS EBIT VS OCF VS FCFMNPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -25.85%, MNPR is in the better half of the industry, outperforming 70.69% of the companies in the same industry.
Looking at the Return On Equity, with a value of -28.32%, MNPR is in the better half of the industry, outperforming 79.04% of the companies in the same industry.
Industry RankSector Rank
ROA -25.85%
ROE -28.32%
ROIC N/A
ROA(3y)-79.42%
ROA(5y)-61.44%
ROE(3y)-100.89%
ROE(5y)-75.25%
ROIC(3y)N/A
ROIC(5y)N/A
MNPR Yearly ROA, ROE, ROICMNPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

MNPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNPR Yearly Profit, Operating, Gross MarginsMNPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

9

2. Health

2.1 Basic Checks

Compared to 1 year ago, MNPR has more shares outstanding
Compared to 5 years ago, MNPR has less shares outstanding
MNPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MNPR Yearly Shares OutstandingMNPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MNPR Yearly Total Debt VS Total AssetsMNPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 29.82 indicates that MNPR is not in any danger for bankruptcy at the moment.
The Altman-Z score of MNPR (29.82) is better than 96.98% of its industry peers.
There is no outstanding debt for MNPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 29.82
ROIC/WACCN/A
WACCN/A
MNPR Yearly LT Debt VS Equity VS FCFMNPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 11.47 indicates that MNPR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 11.47, MNPR belongs to the top of the industry, outperforming 84.37% of the companies in the same industry.
A Quick Ratio of 11.47 indicates that MNPR has no problem at all paying its short term obligations.
MNPR has a better Quick ratio (11.47) than 84.37% of its industry peers.
Industry RankSector Rank
Current Ratio 11.47
Quick Ratio 11.47
MNPR Yearly Current Assets VS Current LiabilitesMNPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

MNPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.08%.
EPS 1Y (TTM)-35.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-358.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 22.63% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.63%
EPS Next 2Y23.28%
EPS Next 3Y24.4%
EPS Next 5Y22.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNPR Yearly Revenue VS EstimatesMNPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
MNPR Yearly EPS VS EstimatesMNPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MNPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MNPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNPR Price Earnings VS Forward Price EarningsMNPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNPR Per share dataMNPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

MNPR's earnings are expected to grow with 24.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.28%
EPS Next 3Y24.4%

More info and screens

0

5. Dividend

5.1 Amount

MNPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MONOPAR THERAPEUTICS INC

NASDAQ:MNPR (5/2/2025, 8:10:52 PM)

44.96

+1.81 (+4.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31 2025-03-31/bmo
Earnings (Next)05-09 2025-05-09
Inst Owners45.53%
Inst Owner Change0.46%
Ins Owners6.62%
Ins Owner Change-2.09%
Market Cap274.71M
Analysts80
Price Target59.84 (33.1%)
Short Float %1.17%
Short Ratio1.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-259.01%
Min EPS beat(2)-541.92%
Max EPS beat(2)23.9%
EPS beat(4)2
Avg EPS beat(4)-126.19%
Min EPS beat(4)-541.92%
Max EPS beat(4)23.9%
EPS beat(8)6
Avg EPS beat(8)-53.82%
EPS beat(12)8
Avg EPS beat(12)-34.52%
EPS beat(16)11
Avg EPS beat(16)-24.1%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)23.51%
PT rev (3m)26.16%
EPS NQ rev (1m)-7.51%
EPS NQ rev (3m)-24.2%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.99
P/tB 4.99
EV/EBITDA N/A
EPS(TTM)-4.12
EYN/A
EPS(NY)-2.65
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0
BVpS9.01
TBVpS9.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.85%
ROE -28.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.42%
ROA(5y)-61.44%
ROE(3y)-100.89%
ROE(5y)-75.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.47
Quick Ratio 11.47
Altman-Z 29.82
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-358.33%
EPS Next Y35.63%
EPS Next 2Y23.28%
EPS Next 3Y24.4%
EPS Next 5Y22.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-82.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.69%
OCF growth 3YN/A
OCF growth 5YN/A